| | Pre-third dose | Post-third dose |
|---|
FC [95%CI] | p value | FC [95%CI] | p value |
|---|
Overall | 0.42 [0.22, 1.21] | 0.0577 | 0.64 [0.22, 1.84] | 0.4079 |
Non-biological | 0.56 [0.17, 1.03] | 0.3903 | 0.80 [0.19, 3.38] | 0.7636 |
Biological | 0.33 [0.10, 1.13] | 0.0775 | 0.47 [0.12, 1.80] | 0.2706 |
JAKi | 0.38 [0.06, 2.56] | 0.3180 | 0.54 [0.07, 3.91] | 0.5418 |
- Cells show Fold-changes (FC), 95% confidence intervals (CI) and p values of the corresponding comparison. FCs and p values were derived from a mixed-effects linear model where sex, age, rheumatic condition, treatment type, use of glucocorticoids, type of vaccine, sample type (pre- or post-third dose) and time from previous dose where included as fixed effects, as well as the interaction between: sex and sample type; treatment and sample type; rheumatic condition and sample type; use of glucocorticoids and sample type; time from second and third vaccine dose and sample type; glucocorticoids use and treatment regimen; and glucorticoids use and rheumatic condition. Individual effects were included as random effects in this model. SLE Systemic Lupus Erythematosus, RA Rheumatoid Arthritis, B27-AS HLA-B27 positive Ankylosing Spondylitis, PSA Psoriatic Arthritis, GCA Giant Cell Arteritis, GCs Glucocorticoids; JAKi JAK inhibitors, GCs Glucocorticoids, FC Fold-Change, 95%CI 95% confidence interval
